ABEO
Abeona Therapeutics Inc.
Biotechnology · Healthcare · United States
4.56
close · 2026-10-29
value
27
cheaper than peers27
quality
75
stronger fundamentals75
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
caveat reports profit, burns cash
Value inputs
| measure | company | vs peers |
| earnings yield, latest year | 16.9% | 95 |
| price to book | 2.04× | 70 |
| forward P/E | 13.92× | 64 |
| price to sales | 13.40× | 49 |
| cash flow yield, latest year | -24.7% | 23 |
| earnings yield, 1 year ago | -25.9% | 23 |
| cash flow yield, 1 year ago | -17.1% | 23 |
| cash flow yield, 3 years ago | -12.8% | 14 |
| earnings yield, 2 years ago | -42.3% | 14 |
| cash flow yield, 2 years ago | -10.9% | 14 |
| earnings yield, 3 years ago | -92.4% | 5 |
11 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 2745.0% | 96 |
| return on equity | -43.1% | 54 |
| operating margin | -120.0% | 54 |
| debt to equity | 15.5% | 51 |
4 of 4 measures available
Facts
| market cap | $261M |
| free cash flow | -$73.4M |
| employees | 226 |
| first trade | 1980-09-19 |
| next earnings | 2026-08-13 |
| fundamentals updated | 2026-09-01 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 1.01 | -1.55 | -2.53 | -5.53 |
| free cash flow | -$84.3M | -$58.5M | -$37.3M | -$43.6M |
| net income | $71.2M | -$63.7M | -$54.2M | -$39.7M |
| revenue | $5.8M | $0 | $3.5M | $1.4M |
| unusual items | $6.1M | -$755,000 | -$10.6M | $5.7M |